Otsuka ICU Medical issues nationwide recall for sodium chloride injection due to product mix-up

AUSTIN, Texas — Otsuka ICU Medical LLC issued a voluntary nationwide recall on Sept. 17, 2026, for one lot of 0.9% Sodium Chloride Injection, USP, in 100 mL single packs, following the discovery of a product mix-up involving 10 mEq Potassium Chloride Injection, according to a PR Newswire report. The recall extends to the user level across the United States, prompting hospital operators and clinical purchasers to immediately inspect their intravenous solution inventories.

Strategic Context

The recall targets a specific lot distributed by Otsuka ICU Medical LLC, impacting standard sterile injectable stockrooms. For health system supply chain directors and hospital procurement officers, the withdrawal of a standard diluent or flush solution necessitates an immediate audit of stockrooms and pharmacy shelves to identify and isolate the affected product. Standard clinical protocols rely on clear distinctions between basic saline solutions and concentrated electrolyte formulations to maintain administration safety.

Financial & Macro Implications

Unscheduled recalls of foundational hospital supplies place immediate demands on pharmacy and procurement teams to secure alternative allocations from secondary vendors. Supply chain managers must account for potential temporary tightness in single-pack 100 mL sodium chloride inventory while replacement shipments are processed and quarantined stock is returned.

Forward Outlook

Facility managers and pharmacy directors must review receiving logs and verify existing stock against the recalled lot numbers issued by Otsuka ICU Medical LLC. Organizations holding the affected product must halt distribution immediately and quarantine the inventory. Consumers and facilities can contact ICU Medical, Inc. directly at 1-844-654-7780 to coordinate return procedures and manage replacement logistics.